Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome
MT Newswires Live
Aug 19
Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.
The regulator has set a target action date for late in Q1 of 2027, the company said.
The application is supported by phase 2b and phase 3 data, which showed a reduction in tic severity and sustained efficacy, Teva said.
Teva Pharmaceutical Industries shares were up 1.8% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.